Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC cut its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 71,500 shares of the biopharmaceutical company’s stock after selling 951 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.06% of Cytokinetics worth $3,363,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Cytokinetics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company’s stock valued at $560,520,000 after purchasing an additional 154,216 shares during the last quarter. LPL Financial LLC grew its stake in shares of Cytokinetics by 6.6% in the fourth quarter. LPL Financial LLC now owns 13,988 shares of the biopharmaceutical company’s stock valued at $658,000 after buying an additional 870 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Cytokinetics in the 4th quarter valued at $1,082,000. American Century Companies Inc. lifted its stake in Cytokinetics by 8.4% during the 4th quarter. American Century Companies Inc. now owns 356,576 shares of the biopharmaceutical company’s stock worth $16,773,000 after acquiring an additional 27,619 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Cytokinetics during the 4th quarter valued at about $303,000.

Insider Transactions at Cytokinetics

In related news, EVP Andrew Callos sold 3,341 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the sale, the executive vice president now owns 64,434 shares in the company, valued at $2,788,059.18. This represents a 4.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert I. Blum sold 16,970 shares of Cytokinetics stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $43.44, for a total transaction of $737,176.80. Following the completion of the transaction, the chief executive officer now owns 364,181 shares in the company, valued at approximately $15,820,022.64. This represents a 4.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,834 shares of company stock worth $1,949,275. Insiders own 3.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CYTK. Stifel Nicolaus started coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 price target on the stock. Evercore ISI raised shares of Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and set a $78.00 price objective on shares of Cytokinetics in a research report on Friday, February 7th. Morgan Stanley set a $67.00 target price on Cytokinetics in a report on Friday, March 7th. Finally, Citigroup started coverage on Cytokinetics in a research report on Friday, February 7th. They issued a “buy” rating and a $86.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $82.00.

Cytokinetics Price Performance

Shares of CYTK opened at $42.99 on Friday. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. Cytokinetics, Incorporated has a 1-year low of $40.53 and a 1-year high of $75.71. The stock has a market cap of $5.09 billion, a PE ratio of -7.99 and a beta of 0.95. The firm has a fifty day moving average price of $45.80 and a 200 day moving average price of $49.67.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million. As a group, sell-side analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.